Login to Your Account



Mixed Results for Xeljanz Challenger

Syk 'Em? Rigel Says RA Data Not Far from Pfizer's Phase III

By Randy Osborne
Staff Writer

Friday, April 5, 2013

Analysts took as less serious one of two primary endpoints that fostamatinib, the oral spleen tyrosine kinase (syk) inhibitor for rheumatoid arthritis (RA), missed in Phase III trial, and focused skeptically instead on the successfully reached goal in the study, known as OSKIRA-1.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription